Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
The Lancet - United Kingdom
doi 10.1016/s0140-6736(16)00559-6
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 1, 2016
Authors
Publisher
Elsevier BV